// App-Quantinova.ai

: Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.

Researchers

Presenter

  • Shubham Pant

Principal Investigators

  • Sant P. Chawla

  • Vincent Chung

  • Giuseppe Del Priore

  • Dae Won Kim

  • Marcus Smith Noel

  • Paul Eliezer Oberstein

  • Allyson J. Ocean

  • Philip Agop Philip

  • Vincent J. Picozzi

  • Diane M Simeone

  • Andrea Wang-Gillam

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Sarcoma Oncology Research Center, Santa Monica, CA

  • City of Hope, Duarte, CA

  • Morehouse School of Medicine, Atlanta, GA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Wilmot Cancer Institute, University of Rochester, Rochester, NY

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

  • Weill Cornell Medical College, New York, NY

  • Karmanos Cancer Institute, Detroit, MI

  • Virginia Mason Medical Center, Seattle, WA

  • NYU Langone Health, New York, NY

  • Washington University School of Medicine, St. Louis, MO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Microphthalmia, syndromic, 9

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Adrucil injection

  • Gemcitabine

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Multicenteric

Phase

  • II/III

Study Id's

  • NCT03512756

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved